Literature DB >> 21778423

Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects.

Marja-Riitta Taskinen1, Martin Adiels, Jukka Westerbacka, Sanni Söderlund, Juhani Kahri, Nina Lundbom, Jesper Lundbom, Antti Hakkarainen, Sven-Olof Olofsson, Marju Orho-Melander, Jan Borén.   

Abstract

OBJECTIVE: Obesity increases the risk of cardiovascular disease and premature death. However, not all obese subjects develop the metabolic abnormalities associated with obesity. The aim of this study was to clarify the mechanisms that induce dyslipidemia in obese subjects. METHODS AND
RESULTS: Stable isotope tracers were used to elucidate the pathophysiology of the dyslipidemia in hypertriglyceridemic (n=14) and normotriglyceridemic (n=14) obese men (with comparable body mass index and visceral fat volume) and in normotriglyceridemic nonobese men (n=10). Liver fat was determined using proton magnetic resonance spectroscopy, and subcutaneous abdominal and visceral fat were measured by magnetic resonance imaging. Serum triglycerides in obese subjects were increased by the combination of increased secretion and severely impaired clearance of triglyceride-rich very-low-density lipoprotein(1) particles. Furthermore, increased liver and subcutaneous abdominal fat were linked to increased secretion of very-low-density lipoprotein 1 particles, whereas increased plasma levels of apolipoprotein C-III were associated with impaired clearance in obese hypertriglyceridemic subjects.
CONCLUSIONS: Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects with similar levels of visceral adiposity. The results emphasize the clinical importance of assessing hypertriglyceridemic waist in obese subjects to identify subjects at high cardiometabolic risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778423     DOI: 10.1161/ATVBAHA.111.224808

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  42 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 2.  Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Authors:  Piers R Blackett; Dharambir K Sanghera
Journal:  J Clin Lipidol       Date:  2012-04-22       Impact factor: 4.766

3.  Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype.

Authors:  V H Telle-Hansen; B Halvorsen; K T Dalen; I Narverud; N Wesseltoft-Rao; L Granlund; S M Ulven; K B Holven
Journal:  Genes Nutr       Date:  2013-01-08       Impact factor: 5.523

4.  Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes.

Authors:  Rakel F Johansen; Esben Søndergaard; Lars Peter Sørensen; Anne Grethe Jurik; Jens S Christiansen; Søren Nielsen
Journal:  Diabetologia       Date:  2016-01-19       Impact factor: 10.122

Review 5.  Dyslipidemia in patients with nonalcoholic fatty liver disease.

Authors:  Hemant Chatrath; Raj Vuppalanchi; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2012-03-13       Impact factor: 6.115

6.  APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Xiaoyun Cheng; Jun Yamauchi; Sojin Lee; Ting Zhang; Zhenwei Gong; Radhika Muzumdar; Shen Qu; H Henry Dong
Journal:  J Biol Chem       Date:  2017-01-23       Impact factor: 5.157

7.  Insulin dependent apolipoprotein B degradation and phosphatidylinositide 3-kinase activation with microsomal translocation are restored in McArdle RH7777 cells following serum deprivation.

Authors:  Janet D Sparks; Amy L Magra; Jeffrey M Chamberlain; Colleen O'Dell; Charles E Sparks
Journal:  Biochem Biophys Res Commun       Date:  2015-11-23       Impact factor: 3.575

Review 8.  Demystifying the management of hypertriglyceridaemia.

Authors:  Gerald F Watts; Esther M M Ooi; Dick C Chan
Journal:  Nat Rev Cardiol       Date:  2013-09-24       Impact factor: 32.419

9.  Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.

Authors:  Yun-Zi Liu; Xiaoyun Cheng; Ting Zhang; Sojin Lee; Jun Yamauchi; Xiangwei Xiao; George Gittes; Shen Qu; Chun-Lei Jiang; H Henry Dong
Journal:  J Biol Chem       Date:  2016-05-11       Impact factor: 5.157

Review 10.  Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Authors:  Niina Matikainen; Marja-Riitta Taskinen
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.